Lifeboat Foundation

From insilico meddicine — the beginning of an AI healthcare revolution.

Poly Mamoshina on Machine Learning for small molecule drug discovery and the beginning of an AI healthcare revolution — interviewed at the Undoing Aging conference in Berlin 2019!

Continue reading “Polina Mamoshina — The Beginning of an AI Healthcare Revolution” »

Nearly one in six deaths from prostate cancer could be prevented if targeted screening was introduced for men at a higher genetic risk of the disease, according to a new UCL-led computer modelling study.

Prostate cancer is the most common form of cancer in men with around 130 new cases diagnosed in the UK every day and more than 10,000 men a year dying as a result of the disease. However, unlike breast and cervical cancer there is currently no national screening programme for this disease in the UK.

A blood test that detects raised levels of the prostate-specific antigen (PSA) can be used to screen for prostate cancer. However, this test is not a reliable indicator as it does not accurately distinguish between dangerous cancers from harmless ones—leading to both unnecessary operations and missed cancers that are harmful.

P53 is the most famous cancer gene, not least because it’s involved in causing over 50% of all cancers. When a cell loses its p53 gene—when the gene becomes mutated—it unleashes many processes that lead to the uncontrolled cell growth and refusal to die, which are hallmarks of cancer growth. But there are some cancers, like kidney cancer, that that had few p53 mutations. In order to understand whether the inactivation of the p53 pathway might contribute to kidney cancer development, Haifang Yang, Ph.D., a researcher with the Sidney Kimmel Cancer Center—Jefferson Health probed kidney cancer’s genes for interactions with p53.

Earlier work found that PBRM1—the second most mutated gene in kidney cancer—could interact with p53. However, other researchers were unable to definitively show that it was truly an important mechanism in kidney cancer.

Rather than looking at the p53 protein itself, first author Weijia Cai a postdoc in Dr. Yang’s lab and other collaborators looked at an activated version of p53, one that is studded with an additional chemical marker—an acetyl group—at many specific spots.

From the beginning of time, humankind has searched for the secret to a long life. Now science may have found an answer, in the form of molecular augury. The pattern of chemical chains that attach to the DNA in your cells—on-off switches known as epigenetic markers—can reveal how swiftly you are aging, and perhaps even how much longer you will live. While genetic testing might tell you where you came from, epigenetics promises a glimpse into the future. Now, a handful of companies are offering commercial blood or saliva tests based on the science of epigenetics—a chance to find out how old you truly are.

Companies claim they can now easily calculate your biological age. Should you take them up on it?

To that end, Fields decided to ask a Florida judge to grant him a warrant that would override the new policy, allowing him to search GEDmatch’s entire database, including users who hadn’t opted in — and Judge Patricia Strowbridge did just that, the detective announced at a recent police convention, according to the NYT.

Legal experts told the NYT that this appears to be the first time a judge has approved a DNA website warrant this broad, with New York University law professor Erin Murphy calling it “a huge game-changer.”

“The company made a decision to keep law enforcement out, and that’s been overridden by a court,” Murphy told the newspaper. “It’s a signal that no genetic information can be safe.”

Rejuvenation Roundup November 2019

Quite a number of readily understandable reviews were published this month, along with an X10 episode on epigenetic alterations; if you’re new to the biology of aging or want to introduce someone else to the topic with new material, this is a great time to start.

LEAF News

Continue reading “Rejuvenation Roundup December 2019” »

Researchers have found a woman with a rare genetic mutation that has protected her from dementia even though her brain has developed major neurological features of the disease.

Half of people who live to 85 will develop Alzheimer’s disease — a disturbing statistic. But research into a family in South America has revealed a gene mutation that appears to afford protection, and may lead to a way to treat or possibly even prevent the disease.

Scientists have developed a new gene-therapy technique by transforming human cells into mass producers of tiny nano-sized particles full of genetic material that has the potential to reverse disease processes.

Though the research was intended as a proof of concept, the experimental therapy slowed tumor growth and prolonged survival in mice with gliomas, which constitute about 80 percent of malignant brain tumors in humans.

The technique takes advantage of exosomes, fluid-filled sacs that cells release as a way to communicate with other cells.